Vertebral osteomyelitis due to Aspergillus fumigatus in a patient with chronic granulomatous disease successfully treated with antifungal agents and interferon-gamma

Medical Mycology

Volumn 48, Issue 3, 2010, Pages 537-541

  Al Tawfiq, Jaffar A ^a   Al Abdely, Hail M ^b  

^a DHAHRAN HEALTH CENTER   (Saudi Arabia)

^b KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

Aspergillus fumigatus; Chronic granulomatous disease; Interferon gamma; Osteomyelitis

Indexed keywords

AMPHOTERICIN B; CASPOFUNGIN; GAMMA INTERFERON; ISONIAZID; ITRACONAZOLE; VORICONAZOLE;

ADOLESCENT; ARTICLE; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CASE REPORT; CHRONIC GRANULOMATOUS DISEASE; CLINICAL FEATURE; CROHN DISEASE; GLUCOSE 6 PHOSPHATE DEHYDROGENASE DEFICIENCY; HUMAN; HUMAN TISSUE; IMMUNE DEFICIENCY; LUNG TUBERCULOSIS; LYMPHADENITIS; MALE; NONHUMAN; RESPIRATORY BURST; SPONDYLITIS;

ADOLESCENT; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CERVICAL VERTEBRAE; DRAINAGE; ECHINOCANDINS; GRANULOMATOUS DISEASE, CHRONIC; HUMANS; INTERFERON-GAMMA; ITRACONAZOLE; MALE; OSTEOMYELITIS; PYRIMIDINES; SAUDI ARABIA; THORACIC VERTEBRAE; TREATMENT OUTCOME; TRIAZOLES;

ASPERGILLUS FUMIGATUS;

EID: 77950581425     PISSN: 13693786     EISSN: 14602709     Source Type: Journal    
DOI: 10.3109/13693780903325290     Document Type: Article

References (21)

1. Winkelstein JA, Marino MC, Johnston RB Jr et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79: 155-169. (Pubitemid 30327530)
2. Ahlin A, Boer MD, Roos D et al. Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta Paediatr 1995; 84: 1386-1394. (Pubitemid 26031055)
3. Ishibashi F, Nunoi H, Endo F, Matsuda I, Kanegasaki S. Statistical and mutational analysis of chronic granulomatous disease in Japan with special reference to gp91-phox and p22-phox defi ciency. Hum Genet 2000; 106: 473-481. (Pubitemid 30406672)
4. Suliaman F, Amra N, Sheikh S, Almuhsen S, Alsmadi O. Epidemiology of chronic granulomatous disease of childhood in eastern province, Saudi Arabia. Ped Asthma Allerg Immun 2009; 22: 21-26.
5. Dotis J, Roilides E. Osteomyelitis due to Aspergillus spp. in patients with chronic granulomatous disease: comparison of Aspergillus nidulans and Aspergillus fumigatus. Int J Infect Dis 2004; 8: 103-110. (Pubitemid 38166076)
6. Espinel-Ingroff A, Fothergill A, Peter J, Rinaldi MG, Walsh TJ. Testing conditions for determination of minimum fungicidal con centrations of new and established antifungal agents for Aspergillus spp.: NCCLS collaborative study. J Clin Microbiol 2002; 40: 3204-3208. (Pubitemid 34977429)
7. Cohen MS, Isturiz RE, Malech HL et al. Fungal infection in chronic granulomatous disease. The importance of the phagocyte in defense against fungi. Am J Med 1981; 71: 59-66.
8. Tsumura N, Akasu Y, Yamane H et al. Aspergillus osteomyelitis in a child who has p67-phox-defi cient chronic granulomatous disease. Kurume Med J 1999; 46: 87-90. (Pubitemid 29254591)
9. Dotis J, Panagopoulou P, Filioti J et al. Femoral osteomyelitis due to Aspergillus nidulans in a patient with chronic granulomatous disease. Infection 2003; 31: 121-124. (Pubitemid 36437729)
10. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ. Enhancement of oxidative response and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun 1993; 61: 1185-1193. (Pubitemid 23099183)
11. Mamishi S, Zomorodian K, Saadat F et al. A case of invasive aspergillosis in CGD patient successfully treated with Amphotericin B and INF-gamma. Ann Clin Microbiol Antimicrob 2005; 4: 4. (Pubitemid 41461204)
12. Errante PR, Frazao JB, Condino-Neto A. The use of interferon-gamma therapy in chronic granulomatous disease. Recent Pat Antiinfect Drug Discov 2008; 3: 225-230.
13. Woodman RC, Erickson RW, Rae J, Jaffe HS, Curnutte JT. Prolonged recombinant interferon-gamma therapy in chronic granulomatous disease: evidence against enhanced neutrophil oxidase activity. Blood 1992; 79: 1558-1562.
14. Condino-Neto A, Newburger PE. Interferon-gamma improves splicing effi ciency of CYBB gene transcripts in an interferon-responsive variant of chronic granulomatous disease due to a splice site consensus region mutation. Blood 2000; 95: 3548-3554.
15. Ishibashi F, Mizukami T, Kanegasaki S et al. Improved superoxidegenerating ability by interferon gamma due to splicing pattern change of transcripts in neutrophils from patients with a splice site mutation in CYBB gene. Blood 2001; 98: 436-441.
16. The International Chronic Granulomatous Disease Cooperative Study Group. A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. N Engl J Med 1991; 324: 509-516.
17. Marciano BE, Wesley R, De Carlo ES et al. Long-term interferongamma therapy for patients with chronic granulomatous disease. Clin Infect Dis 2004; 39: 692-699. (Pubitemid 39180442)
18. Van't Wout JW, Raven EJ, Van Der Meer JW. Treatment of invasive aspergillosis with itraconazole in a patient with chronic granulomatous disease. J Infect 1990 Mar; 20: 147-150. (Pubitemid 20123950)
19. Van't Hek LG, Verweij PE, Weemaes CM et al. Successful treatment with voriconazole of invasive aspergillosis in chronic granulomatous disease. Am J Respir Crit Care Med 1998; 157: 1694-1696. (Pubitemid 28242110)
20. Singh N, Limaye AP, Forrest G, Safdar N. Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study. Transplantation 2006; 81: 320-326.
21. Safdar A. Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin Infect Dis 2002; 34: 1415-1417. (Pubitemid 34507954)